Summary
Background: Home parenteral nutrition (HPN) has been shown to delay deterioration in cancer patients with malnutrition. Its risk-benefit ratio, however, is determined by the threat of central venous catheter (CVC) complications. Only few prospective studies on this subject exist, most of them based on small samples. The objective of this study was to provide reliable estimates of incidence rates of CVC complications in everyday HPN patient care in Germany. Patients and Methods: Aiming for a large prospective cohort study, we cooperated with a service provider caring for HPN patients nationwide. Between July 1 and November 30, 2006, all consecutive adult patients with more than 10 infusion days and no previous history of HPN were recruited. Follow-up ended on January 31, 2007. Data were collected in a standardised way by the provider's staff. To prevent underreporting, we used computer-assisted telephone interviews with medical caregivers as a provider-independent data source. Results: 481 patients met the inclusion criteria, contributing a total of 31,337 catheter days. 52 patients experienced a total of 63 CVC complications, resulting in an incidence rate of 2.01 CVC complications per 1,000 catheter days including 1.02 CVC infections per 1,000 catheter days. Conclusion: HPN administration can be safely performed with a relatively low rate of CVC complications.
Introduction
Malnutrition is frequently observed in chronic and severe disease, and is associated with impaired outcome [1] [2] [3] . In German hospitals, every 4th patient is malnourished. In oncology departments, malnutrition has been found in 38% of the patients [4] . The survival of an incurable cancer patient is not only limited by the tumour itself but also by malnutrition [5] . Home parenteral nutrition (HPN) is widely used to delay or correct malnutrition both in oncological and non-oncological patients [6, 7] . Its risk-benefit ratio, however, is related to the threat of central venous catheter (CVC) complications. In the largest European study [8] , CVC-related complications were observed in 25% of all HPN patients with mostly benign indications and long-term HPN care. 50% of the reported complications were catheter infections, resulting in an incidence of 0.6 infections per 1,000 catheter days. Other international studies reported CVC complication rates between 0.94 and 5.56 per 1,000 catheter days and catheter infection rates between 0.6 and 5.36 per 1,000 catheter days [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . All these studies had some methodological limitations, as only few were prospective, and most were based on small samples of predominantly non-oncological patients from single specialised medical centres. In May 2007, the Deutsche Gesellschaft für Ernährungsme -dizin e.V. (DGEM) published guidelines for parenteral nutrition and emphasised the necessity of monitoring the HPN therapy for complications and effectiveness [22] . Unlike in Denmark, France, or Scotland, in Germany there is no central surveillance of HPN therapy. HPN is managed by many different agencies, including therapy-initiating physicians, general practitioners, outpatient nursing services, HPN providers, and the patients themselves without any central standard. To our knowledge, no large prospective study of the occurrence of CVCrelated complications in HPN patients in Germany exists. Therefore, the aim of our study was to provide an estimate of the incidence of CVC complications in everyday HPN patient care under the conditions of the German healthcare system.
Patients and Methods

Patients and Data Collection
To achieve a large prospective cohort study, we cooperated with a service provider caring for HPN patients nationwide (Travacare GmbH, Hallbergmoos, Germany). Between July 1 and November 30, 2006, all consecutive adult patients of the provider with more than 10 infusion days after hospital discharge and no previous history of HPN were recruited. There were no restrictions regarding diagnosis, indication, expected survival, and planned duration of HPN. Informed consent was signed during the first 10 infusion days at home. A total of 481 patients from 181 centres were included ( fig. 1) Crispin/Thul/Arnold/Schild/Weimann wed at each visit regarding abnormalities in appetite, thirst, and excretion as well as the presence of nausea, vomiting, head-or backache, ascites, or symptoms of catheter complications (e.g. temperature, fever, shivering, infusion abnormalities, exudation, pain, turgor, redness, bleeding close to the catheter). In the time between the visits, patients and outpatient nursing staff could use a memory aid document ('patient's passport') to record abnormalities. Entries in these documents were copied to the official CRF during the next visit. Symptoms indicative of CVC complications were recorded by the provider's staff and corroborated with the patients' attending physicians. Complications were recorded as local infection, systemic infection, CVC obstruction, CVC dislocation, CVC defect, other CVC complication, and/or CVC removal in consequence of a complication. To prevent underreporting, face-to-face data collection was complemented by a second provider-independent information source. This was established in form of computer-assisted (and thus highly standardised) telephone interviews (CATI) with patients, outpatient nursing personnel, general practitioners, and therapy-initiating physicians. 70.3% of all patients recruited gave written consent to these interviews. The interviews were carried out by a specially trained postgraduate public health student at the Department of Medical Informatics, Biometry, and Epidemiology (IBE) of the Ludwig Maximilians University Munich. Contacts with patients and professional caregivers (outpatient nursing personnel, general practitioners, therapy-initiating physicians) were attempted (up to 5 times) in the order of patient recruitment after a minimum of 12 therapy days. A second interview was attempted 4 weeks later. Professionals were asked if and when any of the above CVC complications had occurred and whether the diagnosis was assured. If so, the complication was counted regardless of CRF information recorded during the patient visits. After HPN termination, telephone interviews were performed to investigate the patient's life-status and the cause of death in case of fatal outcomes. Patient interviews were used to trigger additional professional interviews in the case of suspected complications. To minimise the risk of CVC complications, the provider's staff educated patients and outpatient nursing personnel in using a highly structured manual containing text, pictures, and the manufacturers' instructions to illustrate the correct process of preparing the infusion and thus assure aseptic handling even without the use of gloves and gowns. The following parameters were considered as potential risk factors for the incidence of CVC complications: the type of catheter (port system, Broviac/Hickman catheter, other), the use of an infusion pump, the HPN frequency per week, the frequency of dressing and needle changes, the caregiver in charge of dressing and needle changes (patient or a relative, outpatient nursing service, specialised provider), and the use of the patient's catheter for other intravenous therapies beside HPN. To get information about the effect of the HPN therapy, the infusion regimen, the infusion days per week, and the weight during the HPN were recorded.
Statistical Analysis
Descriptive statistics were computed for all variables using adequate measures of location and dispersion. Incidence rates of catheter complications were expressed as events per 1,000 catheter days with 95% confidence in- 
Results
Patient Characteristics and Data of HPN Use
Between July and November 2006, a total of 481 patients were recruited, predominantly elderly patients with malignancies and with port systems ( (table 2) . None of the complications were fatal. Because of the relatively low number of complications, the exploratory analyses failed to identify potential risk factors.
Discussion
The objective of this pilot study was to provide incidence estimates of CVC-related complications in everyday HPN patient care under the conditions of the German healthcare system. During the observational period, an incidence of 2.01 CVCrelated complications per 1,000 catheter days and of 1.02 CVC-related infections were documented. Infections were the most frequent CVC complications (50.8%), followed by CVC occlusions (17.5%) and other CVC defects (6.3%). These figures agree well with results of recently published studies [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] which reported incidences of 0.94-5.56 catheter complications per 1,000 catheter days and 0.60-5.36 catheter infections per 1,000 catheter days, but some differences have to be considered. Most of the previous publications were based on retrospective data, without a defined observational plan: only 4 of them [9] [10] [11] [12] were prospective studies. They re- ported incidences of 0.82-3.86 catheter infections per 1,000 catheter days whereas only one [9] reported an overall incidence of CVC complications (5.56/1,000 catheter days). Moreover, the majority of publications reported on series from single centres with specialised expertise in HPN [9] [10] [11] [14] [15] [16] [17] [18] . They documented the expert standard of specialised centres that may not be generalisable to the setting of everyday care provided by general practitioners and unspecialised outpatient nursing services. Less is known about nationwide care of HPN patients provided by heterogeneous centres. Ireton-Jones and DeLegge [19] published more recent US data from 1997-2001 by using the database of one nutrition support provider. Analysing these data retrospectively, the authors calculated an incidence of 0.66 catheter infections per 1,000 catheter days (95% CI 0.59-0.74). Similar results were found by Baxter and McKee [12] in their audit of the Scottish Home Parenteral Nutrition Managed Clinical Network (0.9 catheter infections per 1,000 catheter days; 95% CI 0.45-1.57).
The underlying disease may affect the incidence of CVCrelated complications. As shown in some studies [8, 20] , the occurrence of catheter complications was significantly lower in patients with malignancies than with benign disease. Since our data are based on a sample of 90.7% patients with malignancies, they should be comparable to those found in studies with a high percentage of oncological patients. These studies [8, 16, 18, 20] reported CVC-related infections of 0.60-5.36 infections per 1,000 catheter days, where 3 of them found lower [8, 20] or similar [18] incidences compared to our estimate of 1.02 infections per 1,000 catheter days. Even the type of catheter has been discussed as risk factor for CVC-related complications. Whereas some studies [10, 20] found no difference in the incidence of CVC-related infections between the externally tunnelled type of CVC (Hickman/Broviac) and the implanted (Port-a-cath) type, others reported a significantly lower incidence in patients with externally tunnelled systems [8, 16] or with implanted port catheters [21] . Seeing these heterogeneous results and classifying the very high percentage of port patients in our study (94.4%) as a German peculiarity, the discussion of this aspect is quite difficult. Indeed, the incidence of CVC-related infections found in a sample with 69.27% port patients [16] was considerable higher than our one. But one of the authors' main conclusions was that training and experience were likely to reduce CVC-related infections. So, the lower-risk type of catheter should not be discussed without including the intensity and quality of education and experience in the daily connecting procedure. But even if the occurrence of CVC-related complications is influenced by a multitude of risk factors, such as the underlying disease, the type of catheter, education and experience in the daily connecting procedure, frequency of infusions, or use of the catheter for other reasons, in our study none of these parameters could be identified as an independent risk factor. Despite the fact that, as mentioned above, this trial is a prospective evaluation with predefined and quality-assured investigational instruments, there are still methodological limitations. The restriction to patients with more than 10 infusion days may have led to overly optimistic incidence estimates. However, our rationale was to exclude patients with HPN administered only during their very last days of life, and for whom guidelines actually do not recommend HPN [5] . Another aspect is that only 70% of the patients gave their consent to telephone interviews. In 41% of the patients, the attending physicians and/or nurses actually took part in a telephone interview. Complication rates in the group with telephone interviews were higher than in patients without. Possible explanations are false-positive findings due to oversensitivity and questionable specificity of data collection by telephone (leading to overestimates), or underreporting of complications in the non-telephone interview group, or both. Nevertheless, this pilot study with its innovative study design is the first step in the development of further studies that lead to the implementation and evaluation of quality standards to maximise excellent patient care and minimise complications and unnecessary costs in consequence of inadequate medical and outpatient care and hospital re-admissions [23] . In response to the limitations of the present study, further studies with data collection from patients of multiple HPN service providers, improved quality control, and 100% corroboration of suspected cases by means of unstructured expert interviews are needed. They should describe a reasonable risk-benefit and cost-benefit ratio in a group of severely ill patients with advanced cancer in the majority of cases, and be able to establish a nationwide high-quality standard.
